Group 1: Company Performance - Eli Lilly has emerged as a leader in the GLP-1 drug category, particularly with its medication tirzepatide, which effectively lowers blood sugar and promotes weight loss [1] - Tirzepatide became the best-selling drug globally last year, surpassing Merck's Keytruda, and is marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss [2] - Sales of tirzepatide have driven Eli Lilly's stock price up by 400% over the past five years, although the stock has seen a decline of about 4% in 2026 [2] Group 2: Recent Acquisitions and Developments - Eli Lilly announced the acquisition of Orna Therapeutics for $2.4 billion, which is developing innovative gene therapies using circular RNA technology [3] - Orna's therapy, ORN-252, aims to enable the patient's body to generate necessary changes to combat diseases, representing a shift from traditional lab-modified treatments [4] - The new therapy is described as "clinical trial-ready," but commercial sales may still be several years away due to the lengthy drug development process [5] Group 3: Pipeline Expansion - In addition to the Orna acquisition, Eli Lilly is actively expanding its pipeline, including a $350 million collaboration with a Chinese biotech firm for immune disorder and cancer treatments [6] - The company also announced a billion-dollar deal with a German firm to develop gene therapies for hearing loss [6]

Group 1: Eli Lilly Overview - Eli Lilly is the most valuable healthcare company globally, with a market cap of approximately $950 billion, and its stock price has increased by 400% over the past five years, largely due to the success of its GLP-1 drugs, Mounjaro and Zepbound [1] Group 2: Amgen's Potential - Amgen is developing a GLP-1 drug called MariTide, which is an injectable treatment that may only need to be administered once a month, offering a more convenient option compared to weekly injectables like Mounjaro and Zepbound [3] - Clinical trials for MariTide indicate it can help individuals lose up to 20% of their body weight over a 52-week period, comparable to existing GLP-1 treatments [4] Group 3: Investment Considerations for Amgen - Amgen's stock has risen by 34% over the past five years and currently trades at a forward P/E multiple of 16, which is significantly lower than Eli Lilly's forward P/E of 32, suggesting Amgen may be undervalued [5][6] - The GLP-1 drug market is projected to exceed $150 billion within the next decade, indicating substantial growth potential for Amgen and other companies in this sector [6]

Core Insights - Eli Lilly has achieved a market capitalization of $1 trillion, becoming the first health-care company to reach this milestone, typically dominated by technology firms [1] - The company's stock has increased over 36% this year, driven by the success of its weight loss injection Zepbound and diabetes treatment Mounjaro, with demand expected to grow as treatment approvals and insurance coverage expand [2] - Analysts predict that the weight loss drug market could exceed $150 billion by the early 2030s, with Eli Lilly likely to maintain a dominant position [3] Company History and Product Development - Eli Lilly was founded in 1876 and has a long history in diabetes treatment, introducing the first commercial insulin in 1923 [4] - The company became publicly traded in 1952 and has historically relied on successful products, including insulins, Prozac, and the polio vaccine, to drive profits [5] - The approval of tirzepatide (Mounjaro) in May 2022 marked a significant milestone, allowing Eli Lilly to compete with Novo Nordisk's Ozempic in the diabetes market [5] Drug Mechanism and Market Competition - Tirzepatide mimics two gut hormones, GLP-1 and GIP, which help reduce food intake and appetite, while Novo Nordisk's semaglutide (Ozempic) only targets GLP-1 [6] - Mounjaro achieved "blockbuster" status, generating over $1 billion in annual sales during its first full year, and has since been approved for obesity treatment as Zepbound, competing with Novo Nordisk's Wegovy [7]